Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease
Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease
复制标题
DOI：
10.1080/00325481.2022.2074700
复制
发表时间：
2022-05-15
影响因子：
4.2
通讯作者：
Bulbul, Mehmet
中科院分区：
文献类型：
--
作者：
Arslanoglu Aydin, Elif;Baglan, Esra;Bulbul, Mehmet
目的在所有国家广泛获得安全有效的新冠肺炎疫苗是结束新冠肺炎大流行的最大希望。然而，在发展中国家，社会对疫苗接种的犹豫不决是公共卫生方面的一个重要问题。本研究旨在调查风湿病儿童人群对新冠肺炎疫苗的可接受性和耐受性，以及对这些疫苗的态度。方法本研究为观察性、横断面、单中心研究。这项研究包括至少有一种风湿病诊断的儿童患者，以调查患者和家庭对新冠肺炎疫苗的接受性和安全性。结果本研究共纳入228例风湿病患者。99例(43.4%)为幼年特发性关节炎。105名(46%)的患者使用生物制剂治疗他们的风湿病，而123名(54%)的患者没有使用生物制剂。所有患者均未观察到与新冠肺炎疫苗相关的严重不良反应。所有患者均未观察到疾病活化现象。结论评价新冠肺炎疫苗治疗儿童风湿病的安全性和疾病进展的研究较少。尽管这项研究有一些局限性，比如不同诊断的患者的样本量很小，但似乎没有发现风湿病患者接种新冠肺炎疫苗相关危害的增加。
Objectives Wide spread availability of safe and effective vaccines for COVID-19 in all countries is the best hope to end the COVID-19 pandemic. However, in developing countries, the hesitancy of the society about vaccination is an important problem in terms of public health. This study aimed to investigate the acceptability and tolerability of COVID-19 vaccines in the pediatric population diagnosed with rheumatic disease, as well as the attitudes toward these vaccines. Methods This is an observational, cross sectional, single center study. Pediatric patients with at least one diagnosis of rheumatic disease were included in this study to investigate patient and family acceptability and safety of COVID-19 vaccines. Results A total of 228 patients with rheumatic disease were included in this study. Ninety nine (43.4%) of the patients were juvenile idiopathic arthritis. One hundred and five (46%) of the patients were using biological agent treatment for their rheumatic disease, whereas 123 (54%) of the patients were not. No serious adverse effect related to the COVID-19 vaccine were observed in any of the patients. No disease activation was observed in any of them. Conclusion There are only a few studies evaluating of the safety and disease flare of COVID-19 vaccines in children with rheumatic disease. Although this study has some limitations, such as the small sample size of patients with different diagnoses, it appears that there is no increase in COVID-19 vaccination-related harms in the patients with rheumatic disease.